logo
Plus   Neg
Share
Email

Aratana Therapeutics Appoints Craig Tooman As President, CEO

Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on dogs and cats, announced late Thursday that its Board of Directors has appointed Craig Tooman to serve as President and Chief Executive Officer. He was also elected to the Board.

Effective January 17, 2019, Steven St. Peter has resigned from the role of President and Chief Executive Officer and from the Board. St. Peter is a founder of Aratana and served as President and CEO of Aratana since 2012.

Tooman was the first independent member of Aratana's Board of Directors from April 2012 to November 2013. He served as Chair of the Audit Committee before transitioning to Chief Financial Officer for Aratana in November 2013.

Earlier, Tooman has served as Chief Executive Officer of Avanzar Medical, Inc. and Chief Financial Officer for Enzon Pharmaceuticals and Ikaria Inc. He has also held key executive roles at ILEX Oncology, Inc. and Pharmacia Corp.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
WD-40 Company recalled about 130,000 units of X-14 Mildew Stain Remover for potential risk of skin irritation, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said pressure can build up inside the bottle and cause it to fall over and leak, posing a risk of skin irritation. Biopharmaceutical company Bristol-Myers Squibb Co. on Thursday reported a loss for the second quarter, compared to a profit last year, hurt primarily by hefty amortization expenses. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. Looking ahead, the company raised its adjusted earnings and revenue outlook for the full-year 2020. Shares of Deutsche Lufthansa AG were losing around 3 percent in German trading after the airline reported Thursday a loss in its second quarter, compared to prior year's profit with sharply lower revenues with collapse in demand for air travel due to the Corona pandemic. Going ahead, the airline projects a clearly negative adjusted EBIT in the second half of 2020 and a further significant decline
Follow RTT